Article
Oral Microbiota Associated with Clinical Efficacy of Ustekinumab in Crohn’s disease
2024-08-09
Abstract excerpt
<title>Abstract</title> <p>Crohn’s disease (CD) is a chronic inflammatory gastrointestinal disease. Ustekinumab (UST) has been utilized as a therapeutic option for CD patients. However, approximately 40–60% of patients exhibit an inadequate response to UST. Accumulating evidence has confirmed the involvement of oral bacteria in the development of CD. Nevertheless, the relationship between oral microbiota and the...
Topics
Open a Topic to create a Post that cites this publication.
Identifiers and source
- Literature Corpus work
- d1cbfa49-fa58-51fa-bbc9-4dd1f8be1345
- DOI
- 10.21203/rs.3.rs-4705774/v1
